Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

OGT to Host Company Showcase at BioTrinity 2012

Published: Monday, April 23, 2012
Last Updated: Monday, April 23, 2012
Bookmark and Share
Seminar to discuss company’s biomarker accelerator strategy for optimizing drug and diagnostic development.

Oxford Gene Technology (OGT) will be discussing its biomarker discovery offering at the European Biopartnering and Investment Conference, BioTrinity, from 24th-26th April in Newbury, UK.

The conference will include a Company Showcase from OGT’s CEO, Dr Mike Evans, which takes place at 4.20 pm on Wednesday 25th April.

The talk will provide an overview of OGT’s corporate strategy, which has delivered significant and sustained revenue growth, with particular focus on the company’s Diagnostic Biomarkers business unit.

OGT Diagnostic Biomarkers utilizes proprietary next generation technologies to identify informative biomarkers for early-stage detection of cancer and autoimmune disease.

Through a combination of the implementation of a unique Biomarker Accelerator Strategy and in-house discovery, OGT is building a rich patent-protected portfolio of promising biomarkers for a number of diseases where there are clear clinical needs and markets for improved diagnostic tests.

Details of this strategy and OGT’s additional biomarker discovery and validation services will be given in the presentation.

In a recent example of OGT’s Biomarker Accelerator Strategy, OGT entered into an exclusive licensing deal with Inven2, the technology transfer office at Oslo University Hospital and the University of Oslo.

Using 12 highly promising colorectal cancer tissue biomarkers developed at Oslo University Hospital, OGT now has an exclusive license to commercialize any resulting test developed with the biomarkers.

As a well-established private molecular diagnostics and clinical solutions company actively operating in 30 countries worldwide, OGT has a strong position in the large and rapidly growing molecular medicine market.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos